文献速递外周动脉疾病

术后双联抗血小板治疗对慢性肢体威胁性缺血患者下肢血管内治疗结局的影响:基于血管质量倡议-医疗保险关联数据库的分析

The impact of postoperative dual antiplatelet therapy on outcomes of endovascular therapies in patients with chronic limb-threatening ischemia in the Vascular Quality Initiative-Medicare-linked database.
PubMed 文献 · J Vasc Surg · 2025-03-18

该多中心回顾性分析纳入2011至2019年因腹股沟下闭塞性疾病行血管内治疗的慢性肢体威胁性缺血患者,按出院抗血小板方案分为双联抗血小板治疗组(n=14,081)与单联抗血小板治疗组(n=10,086)。双联抗血小板治疗与1年及5年无截肢生存改善相关,但与单用P2Y12抑制剂相比无显著差异;作者认为该结果支持血管内治疗后使用双联抗血小板治疗或P2Y12抑制剂,但需进一步前瞻性研究证实。

要点

  • 双联抗血小板治疗组1年无截肢生存为67.9%,单联抗血小板治疗组为63.7%(P < .001)。
  • 校正混杂因素后,双联抗血小板治疗与1年主要截肢或死亡风险降低相关(aHR 0.82)。
  • 双联抗血小板治疗与单用P2Y12抑制剂相比,结局无显著差异。

核心结论

  • 在慢性肢体威胁性缺血患者中,下肢血管内治疗后双联抗血小板治疗与单联抗血小板治疗相比,与长达5年的无截肢生存改善相关。
  • 双联抗血小板治疗与单用P2Y12抑制剂相比无差异;P2Y12抑制剂与阿司匹林相比与长达5年的无截肢生存改善相关。
  • 作者认为研究结果支持下肢血管内治疗后使用双联抗血小板治疗或P2Y12抑制剂,但需进一步前瞻性研究证实。

研究设计与样本

  • 多中心回顾性分析,数据来自血管质量倡议-医疗保险关联数据库(血管植入物监测与介入结局网络),前瞻性收集。
  • 查询2011年至2019年因腹股沟下闭塞性疾病行血管内治疗的患者,按出院抗血小板方案分为双联抗血小板治疗组(n=14,081,58.3%)与单联抗血小板治疗组(n=10,086,41.7%)。
  • 单联抗血小板治疗组接受阿司匹林或P2Y12抑制剂,双联抗血小板治疗组接受两者。
  • 主要结局为1年及5年无截肢生存;次要结局包括1年及5年总生存、保肢(免于主要截肢)及免于再干预。
  • 采用Kaplan-Meier生存估计和Cox回归分析。

主要发现

  • 1年无截肢生存:双联抗血小板治疗组67.9% vs 单联抗血小板治疗组63.7%(P < .001);5年无截肢生存:双联抗血小板治疗组30.4% vs 单联抗血小板治疗组24.6%(P < .001)。
  • 校正混杂因素后,双联抗血小板治疗与1年主要截肢或死亡风险降低相关(aHR 0.82;95%CI 0.75-0.89;P < .001),5年亦相关(aHR 0.91;95%CI 0.84-0.99;P = .027)。
  • 双联抗血小板治疗与1年死亡风险降低相关(aHR 0.90;95%CI 0.81-0.99;P = .048),与1年主要截肢风险降低相关(aHR 0.86;95%CI 0.79-0.93;P < .001),但5年时未达统计学显著。
  • 再干预未受抗血小板治疗策略影响。
  • 亚组分析显示,双联抗血小板治疗组与单用阿司匹林组相比5年总生存和无截肢生存更优;单用P2Y12抑制剂组与单用阿司匹林组相比5年总生存和无截肢生存也更优;双联抗血小板治疗与单用P2Y12抑制剂相比结局无显著差异。

临床怎么用

  • 作者认为研究结果支持在慢性肢体威胁性缺血患者下肢血管内治疗后使用双联抗血小板治疗或P2Y12抑制剂。
  • 作者指出需进一步前瞻性研究证实该发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The beneficial effects of dual antiplatelet therapy (DAPT) compared with single antiplatelet therapy (SAPT) have been well-established in coronary and carotid endovascular interventions; however, no consensus exists to the role of DAPT in lower extremity endovascular therapies (ETs). We aimed to investigate the impact of postoperative DAPT after ET in patients presenting with chronic limb-threatening ischemia (CLTI) in the Vascular Quality Initiative-Medicare-Linked (Vascular Implant Surveillance and Interventional Outcomes Network) database. METHODS: The study was a multicenter retrospective analysis of prospectively collected Vascular Quality Initiative-Medicare-linked data. The Vascular Implant Surveillance and Interventional Outcomes Network database was queried for all ETs performed for infrainguinal occlusive disease between 2011 and 2019. The patients were stratified by discharge antiplatelet regimen (DAPT vs SAPT). SAPT patients received either aspirin or P2Y12 inhibitors whereas DAPT patients received both. The primary outcome was 1- and 5-year amputation-free survival (AFS). The secondary outcomes included 1- and 5-year overall survival, limb salvage (freedom from major amputation), and freedom from reintervention. Kaplan-Meier survival estimates and Cox regression were used for analysis. RESULTS: The study included two cohorts: SAPT (n = 10,086 [41.7%]) and DAPT (n = 14,081 [58.3%]). Patients in SAPT cohort were older than their DAPT counterparts and were more likely to have congestive heart failure and chronic kidney disease. Patients in the DAPT cohort were more likely to have diabetes and coronary artery disease. In survival analyses, compared with SAPT, 1-year AFS in the DAPT cohort was 67.9% vs 63.7% (P < .001) and 5- year AFS was 30.4% vs 24.6% (P < .001). After adjusting for potential confounders, DAPT was associated with reduced hazards of major amputation or death at 1-year (adjusted hazard ratio [aHR], 0.82; 95% confidence interval [CI], 0.75-0.89; P < .001) and 5-year (aHR, 0.91; 95% CI, 0.84-0.99; P = .027). DAPT was also associated with lower hazards of death (aHR, 0.90; 95% CI, 0.81-0.99; P = .048) and major amputation (aHR, 0.86; 95% CI, 0.79-0.93; P < .001) at 1 year but not 5 years. Reintervention was not impacted by the antiplatelet therapy strategy. In our subanalysis, we found superior 5-year overall survival and AFSs in patients receiving DAPT compared with aspirin alone and also in patients receiving P2Y12 inhibitor alone compared with aspirin alone. However, the outcomes of DAPT vs P2Y12 inhibitor alone were not significantly different. CONCLUSIONS: In this large Medicare-linked national analysis, we found that DAPT is associated with improved AFS up to 5 years after ET in patients with CLTI compared with SAPT. However, there was no difference between DAPT and P2Y12 inhibitor alone. Additionally, P2Y12 inhibitor was associated with improved AFS up to 5 years compared with aspirin. Our findings support the use of DAPT or P2Y12 inhibitor after ETs performed in the lower extremity for CLTI; however, further prospective studies are required to confirm our findings.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Zarrintan S, Hamouda M, Moacdieh MP, et al. The impact of postoperative dual antiplatelet therapy on outcomes of endovascular therapies in patients with chronic limb-threatening ischemia in the Vascular Quality Initiative-Medicare-linked database. J Vasc Surg. 2025. PMID: 40113185. doi:10.1016/j.jvs.2025.03.177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。